Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | GALK1 | P51570 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | AMY1A | P0DUB6 | 7/20 | 0.56 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419547 | 1.00 | KMT2A (0.60) | KMT2AMEN1GAAL3MBTL1POLB | |
| SCHEMBL3678658 | 0.91 | KMT2A (0.72) | KMT2AMEN1GAAL3MBTL1POLB | |
| SCHEMBL3678657 | 0.91 | KMT2A (0.72) | KMT2AMEN1GAAL3MBTL1POLB | |
| SCHEMBL5476893 | 0.87 | KMT2A (0.58) | KMT2AMEN1GAAL3MBTL1POLB | |
| SCHEMBL5476898 | 0.87 | KMT2A (0.58) | KMT2AMEN1GAAL3MBTL1POLB | |
| SCHEMBL445329 | 0.80 | PRMT5 (0.45) | KMT2AMEN1GAAL3MBTL1POLB | |
| SCHEMBL445331 | 0.80 | PRMT5 (0.45) | KMT2AMEN1GAAL3MBTL1POLB | |
| SCHEMBL29010258 | 0.79 | KMT2A (0.82) | KMT2AMEN1GAAL3MBTL1POLB | |
| SCHEMBL28473982 | 0.79 | KMT2A (0.82) | KMT2AMEN1GAAL3MBTL1POLB | |
| SCHEMBL28967925 | 0.79 | KAT8 (0.78) | KMT2AMEN1GAAL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335517-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | RENASCIENCE CO LTD (JP) | 2014-11-13 | — | — | US | disclosed |
| US-8809329-B2 | Detection and treatment of schizophrenia | TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) | 2014-08-19 | — | — | US | disclosed |
| EP-2662453-A2 | Detection and treatment of schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | disclosed |
| EP-2189537-A1 | DETECTION AND TREATMENT OF SCHIZOPHRENIA | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-7645882-B2 | Inhibitor of protein modification products formation | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070123577-A1 | Inhibitor of protein modification products formation | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2007-05-31 | — | — | US | disclosed |
| EP-1693369-A1 | PROTEIN MODIFIER PRODUCTION INHIBITOR | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2006-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123577-A1 | Inhibitor of protein modification products formation | SERPINB6, PROC, PLPBP | KMT2A 2334/4885MEN1 1277/4885GAA 3516/4885 |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | KMT2A 1703/4885MEN1 4818/4885GAA 833/4885 |
| US-20120065198-A2 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | KMT2A 1703/4885MEN1 4818/4885GAA 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.